Search for a command to run...
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), a novel condition induced by viral infections, presents a significant challenge owing to its propensity to trigger thrombotic events. The current strategies for managing and treating SARS-CoV-induced thrombotic conditions primarily focus on early recognition and risk assessment based on age, comorbidities, D-dimer levels, severity of illness, and early detection through comprehensive diagnostic protocols such as imaging techniques and laboratory biomarkers. Treatment modalities that encompass anticoagulation therapy tailored to individual risk profiles and emerging therapies targeting specific pathophysiological mechanisms are also included. Anticoagulation therapy plays a central role, and tailored regimens based on thrombotic severity and patient-specific factors are recommended to prevent the progression and recurrence of thrombosis. Supportive care measures such as respiratory support and fluid management are essential for managing severe cases. Furthermore, the role of supportive care and preventive measures in mitigating complications associated with thrombosis has been emphasized. Finally, ongoing research initiatives and future directions aim to refine therapeutic approaches and improve outcomes for patients affected by SARS-CoV-induced thrombotic conditions. Thus, by implementing various strategies, healthcare providers can effectively manage thrombosis induced by SARSCoV. Collaborative efforts among infectious disease specialists, hematologists, and intensivists are vital for optimizing outcomes in patients affected by SARS-Co- -induced thrombotic events.